News

The assistant member of the department of malignant hematology at Moffitt Cancer Center discussed unmet needs in acute myeloid leukemia and how UCART123v1.2 may address these.

The assistant member of the bone marrow transplant department at St. Jude Children’s Research Hospital discussed new data from a phase 1/2 trial presented at ASH 2022.

Annualized bleed rate and FVIII infusion rates significantly decreased after infusion with the gene therapy.

Four of 17 patients who received UCART123v1.2 showed clinical benefit.

The professor at University Hospital Dresden discussed data presented at the 2022 ASH meeting.

The complete metabolic response rate was 70% 3 months after infusion.

The study's primary investigator shared his thoughts on where CART-ddBCMA could fit within the treatment landscape.

Rates of complete response to the novel CAR-T varied from 67% to 75% across the 4 dosage levels tested.

The assistant member of the bone marrow transplant department at St. Jude Children’s Research Hospital discussed the session she moderated at the ASH 2022 annual meeting.

A complete response rate of 67% was reported and no treatment-limiting toxicity occurred.

A DCE analysis weighed gender-, age-, and disease-severity-specific annual costs as opposed to traditional cost-effectiveness models.

Additional data on 2 patients who developed persistent anemia suggests a genetic cause may be behind the serious adverse event.

Achilles Therapeutics presented updated data from CHIRON and THETIS at the 2022 ESMO immuno-oncology congress.

AVROBIO plans to initiate a global phase 2/3 trial of AVR-RD-02 in GD3 in the second half of 2023.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The allogeneic mesenchymal stem cell therapy trial will enroll patients ineligible for treatment with the autologous CardiAMP.

The first 2 participants dosed are free of vaso-occlusive events as of 5 and 1.5 months of follow-up after treatment with EDIT-301.

Ivan Horak, MD, discussed Tessa’s cell therapy platforms and the ACTION clinical trial.

Updated data were presented at the AES annual meeting in Nashville.

Patients with non-Hodgkin lymphoma in Nkarta's phase 1 study had a 75% complete response rate.

The associate professor from the Medical College of Wisconsin discussed how to address unmet needs with CAR T-cell therapies.

Initial safety data from the PRODYGY study are expected in 2023.

Beam Therapeutics provided data on genomic rearrangement, off-target edits and from a cytokine independent growth assay to the FDA in November 2022.

Review top news and interview highlights from the week ending December 2, 2022.

Updated data from 3 of the company’s programs were presented at an R&D showcase.

OPGx-001 is the first of Opus Genetics’ gene therapy candidates for treating LCA to enter clinical trials.

Sensorion indicated it is still on track to submit a clinical trial application in the first half of next year.

The director of clinical research at Sierra Eye Associates discussed unmet needs in patients with wet AMD.